Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listLanreotide Acetate

Lanreotide Acetate

Synonym(s):3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate;BIM-23014C

  • CAS NO.:127984-74-1
  • Empirical Formula: C54H69N11O10S2
  • Molecular Weight: 0
  • MDL number: MFCD00873576
  • Update Date: 2024-04-12 23:00:59
Lanreotide Acetate Structural

What is Lanreotide Acetate?

Description

Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated.

Originator

Beaufour-Ipsen (France)

The Uses of Lanreotide Acetate

Lanreotide acetate has been used as an inhibitor to test the plasticity of hydrogen sulfide modulation by growth hormone/thyroid hormone signaling in wild-type mice. It is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma.    

The Uses of Lanreotide Acetate

Lanreotide Acetate is a drug used in the control and prevention of glycemia and hypoglycemic brain damage without surgery in patients diagnosed with congenital hyperinsulinism. It improves outcomes in patients suffering from acromegalyresulting from invasive pituitary macroadenoma.

brand name

Somatuline LP

Biochem/physiol Actions

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.

Clinical Use

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007. Lanreotide acetate is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA) and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.). In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

Side Effects

The side effects of Lanreotide Acetate include: Blurred vision; chest pain or discomfort; dizziness; gaseous abdominal or stomach pain; headache; lightheadedness, dizziness, or fainting; nervousness; pale skin; pounding in the ears; recurrent fever; slow, fast, or irregular heartbeat; stomach fullness; troubled breathing with exertion; unusual bleeding or bruising; unusual tiredness or weakness; yellow eyes or skin.

Properties of Lanreotide Acetate

Melting point: >165°C (dec.)
storage temp.  -20°C
solubility  DMSO (Slightly), Methanol (Slightly)
form  powder
color  white to off-white

Safety information for Lanreotide Acetate

Signal word Warning
Pictogram(s)
ghs
Health Hazard
GHS08
GHS Hazard Statements H361:Reproductive toxicity
Precautionary Statement Codes P281:Use personal protective equipment as required.

Computed Descriptors for Lanreotide Acetate

InChIKey PUDHBTGHUJUUFI-UHFFFAOYSA-N
SMILES S1CC(NC(=O)C(N)CC2=CC=C3C(=C2)C=CC=C3)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2C3=C(NC=2)C=CC=C3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C(NC(C(=O)N)C(O)C)=O)CS1

Related products of tetrahydrofuran

You may like

  • 127984-74-1 Lanreotide Acetate 98%
    127984-74-1 Lanreotide Acetate 98%
    127984-74-1
    View Details
  • 127984-74-1 98%
    127984-74-1 98%
    127984-74-1
    View Details
  • Lanreotide acetate 98% (HPLC) CAS 127984-74-1
    Lanreotide acetate 98% (HPLC) CAS 127984-74-1
    127984-74-1
    View Details
  • Lanreotide acetate CAS 127984-74-1
    Lanreotide acetate CAS 127984-74-1
    127984-74-1
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.